(Date:5/12/2008)...w.cryocath.com Toronto Stock Exchange Symbol: CYT...ath(R) Technologies,Inc., the global leader in cry...day announced financial results for the second qua...arter Financial and Operational Highlights:, - ...lion or a 37.6% increase over comparable elec...
(Date:5/12/2008)...ay 12 /PRNewswire-FirstCall/ -- Mesa Laboratories,...ard of Directors has,declared a regular quarterly ...ck, payable on June 13, 2008 to shareholders of re...esa Laboratories develops, acquires, manufactures ... for industrial, pharmaceutical and,medical applic...
(Date:5/12/2008)...ices at shorter distances improved motor scores, r...thDay News) -- A few millimeters can make a huge d...ectrodes surgically implanted in the brain, a new ...ate the subthalamic nucleus, a part of the brain p...le with Parkinson,s disease reduce their medicatio...
(Date:5/12/2008)... younger a child is at diagnosis, study finds, ... Only about 5 percent of people with multiple scl...ke adults with MS, the disease can affect cognitiv... and possibly low IQ scores. , And, the younge...kely he or she is to have a low IQ, according to n...
Breaking Medicine News(10 mins):Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Electrode Placement Key to Brain Stimulation for Parkinson's Patients 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3(Date:5/8/2008)...ANSE demonstrated significant improvement in ADHD ...-FirstCall/ -- Shire plc (LSE: SHP,Nasdaq: SHPGY)...today,presented the results of a phase III pivotal...mprovements in Attention Deficit Hyperactivity,Dis... and efficacy,endpoints., "Adults with ADHD often...
(Date:5/8/2008)...AMPA, Fla., May 8 /- Alphar...utical company, today announced results from,clini...ne sulfate,extended-release with sequestered naltr...lly relevant features addressing abuse liability,a...The Phase I and II,studies, presented at the 27th ...
(Date:5/8/2008)...reatment Provides "Blueprint" to Produce Therapeut...ll., May 8 /PRNewswire-USNewswire/ -- Using gene,t...hting proteins through,skin flaps placed on cancer...tumor volume, according to a study in the May issu...ficial medical journal of the American,Society of ...
(Date:5/8/2008)...lts presented at the 27th Annual Meeting of the Am... (APS), SMYRNA, Ga., May 8 /- Patie... pain relief from diabetic neuropathic pain (DNP),...o data presented at the,27th annual meeting of the...s is the first placebo-controlled trial of a diabe...
Breaking Medicine Technology:Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 3Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 4Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4J D Power and Associates Celebrates 40th Anniversary of Representing the Voice of the Customer 15634 1J D Power and Associates Celebrates 40th Anniversary of Representing the Voice of the Customer 15634 2J D Power and Associates Celebrates 40th Anniversary of Representing the Voice of the Customer 15634 3J D Power and Associates Celebrates 40th Anniversary of Representing the Voice of the Customer 15634 4J D Power and Associates Celebrates 40th Anniversary of Representing the Voice of the Customer 15634 5Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 1Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 2Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 3Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 4Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 5Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 6Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 7Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 8Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4332 9Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 1Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 2Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 3Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 4Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 5ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones 1658 1ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones 1658 2...E)--May 30, 2007 - Rexahn,Pharmaceuticals, Inc. (O... to the discovery, development, and commercializat...ervous system disorders,sexual dysfunction and ot...John Marshall, Principal Investigator of Phase I c...d RX-0201 (Archexin),will present results of the ...
...al Trials for Organ Transplantation, HORSHOLM, Den...ycle Pharma announces positive Phase I clinical re...CP-Tacro - Heads into US,Phase II clinical trials ...a A/S (OMX:LCP) announces positive results,from it...roprietary, once-daily tacrolimus tablet. , A seri...
Other Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Store microscope slides with ease, speed, efficiency.
...ers for just about everything imaginable that migh...ch box is designed for long term storage under arc...f wood over metal systems is overlooked, while the...d of desiccator and insulator, providing an enviro...
A prepared Microscope Slide Cataloging and Storage System.
Our moisture resistant, plastic covered corrugated boxes interlock to stack ten high, each supporting up to 500 lbs of overhead cassette and slide weight. Each box accommodates 2000 slides or 500 tis
Medicine Products: